CN-121987652-A - Application of polifeprosan in preventing and treating parkinsonism

Abstract

The present invention belongs to the field of pharmaceutical technology and discloses the use of epigallocatechin gallate in the prevention and treatment of Parkinson's disease. Specifically, the use of a compound of formula (I), hesperidin, in the prevention and treatment of Parkinson's disease has been disclosed. Pharmacological experiments have shown that 14 days of administration of hesperidin can significantly improve motor coordination dysfunction induced by MPTP in Parkinson's disease, as well as alleviate the decrease in tyrosine hydroxylase expression levels in the substantia nigra striatum caused by MPTP. The results indicate that hesperidin has significant pharmacological activity in preventing and treating Parkinson's disease. Therefore, Jin Shi silkworm glycosides can be used to prepare drugs for the prevention and treatment of Parkinson's disease, with high clinical application value and development prospects.

Inventors

• WANG YUEHUA
• DU GUANHUA
• Feng Wandi

Assignees

• 中国医学科学院药物研究所

Dates

Publication Date

20260508

Application Date

20241105

Claims (3)

1. 1. The application of the compound of the formula (I) of the polifeprosan or the pharmaceutically acceptable salt thereof in preparing the medicines for preventing and treating the parkinsonism;
2. 2. The use according to claim 1, wherein said parkinson's disease comprises impaired postparkinsonian motor coordination.
3. 3. The use according to claim 1, wherein said parkinson's disease comprises reduced expression of the striatal tyrosine hydroxylase enzyme of the postparkinsonism brain.

Description

Application of polifeprosan in preventing and treating parkinsonism Technical Field The invention belongs to the technical field of medicines, and relates to application of polifeprosan in preparing medicines for preventing and treating parkinsonism. Background Parkinsonism is a clinical syndrome associated with motor function and is characterized by tremor, hypokinesia, stiffness, and balance disorders, and can be divided into primary parkinsonism and secondary parkinsonism. Among primary parkinsonism, parkinsonism (PD) patients account for the vast majority of diseases occurring in the elderly's central nervous system degenerative changes, clinically characterized by tremors, myotonia, bradykinesia, and accompanied by brain nigral dopaminergic neuron degeneration death, and reduced striatal dopamine neurotransmitter levels. Secondary parkinsonism is parkinsonism caused by drugs, toxins, head trauma, metabolic diseases, infections, cerebrovascular diseases, etc., characterized by degeneration and necrosis of nigra, striatal dopaminergic neurons, resulting in reduced dopamine synthesis or destruction of the dopamine receptor system, which results in a series of neurological dysfunction. At present, the medicines for treating the parkinsonism mainly comprise medicines such as levodopa tablet, amantadine hydrochloride, phenyllansoprazole hydrochloride, selegiline hydrochloride, ropinirole hydrochloride and the like, but have certain limitation in clinical application, and have important significance in developing new medicines for preventing and treating the parkinsonism. 1-Methyl-4-phenyl-1, 2,3, 6-tetrahydropyridine (MPTP) -induced PD model mice are a common animal model for evaluating drugs for preventing and treating parkinson's disease. Tyrosine hydroxylase (Tyrosine hydroxylase, TH) is a key enzyme in the dopamine biosynthetic pathway and is a recognized marker for dopaminergic neurons. The present study evaluated the anti-PD effect of chrysosporium glycoside in MPTP-induced PD model mice. The cinchonidine (Poliumoside, POL) is the main active ingredient of herba cistanches (CISTANCHE SINENSIS G. Beck) and Callicarpa kwangtungensis (CALLICARPA KWANGTUNGENSIS CHUN) and has anti-inflammatory, antioxidant, hemostatic and other biological activities. At present, no report is made about the application of the polifeprosan in preventing and treating parkinsonism. Disclosure of Invention One of the problems to be solved by the invention is to provide the application of the polifeprosan in improving the motor coordination ability injury of parkinsonism mice. The second problem to be solved by the invention is to provide the application of the poliomycoside in improving the reduction of the expression of the brain nigrostriatal tyrosine hydroxylase of the parkinsonism mice. In order to solve the technical problems of the invention, the invention provides the following technical scheme: The first aspect of the technical scheme of the invention provides application of a compound of the formula (I) of the chrysosporium glycoside or pharmaceutically acceptable salt thereof in preparing medicaments for preventing and treating parkinsonism; the parkinsonism comprises parkinsonism motor coordination ability impairment. The cerebral apoplexy comprises the reduction of the expression of the striatum tyrosine hydroxylase after Parkinson. A compound of formula (I) of polifeprosan or its pharmaceutically acceptable salt for preventing and treating motor coordination function injury after Parkinson use of brain black striatum tyrosine hydroxylase expression reduction in medicine. The invention evaluates the effect of the polifeprosan on the Parkinson by applying MPTP to induce the model mice, and discovers that the polifeprosan can improve the damage of the motor coordination ability of the Parkinson mice and the reduction of the striatum tyrosine hydroxylase. The invention also relates to pharmaceutical compositions of the compounds of the invention and conventional pharmaceutical excipients or auxiliaries. Pharmaceutical compositions of the compounds of the present invention may be prepared according to methods well known in the art. For this purpose, the compounds of the invention may, if desired, be combined with one or more solid or liquid pharmaceutical excipients and/or auxiliaries, in suitable administration forms or dosage forms which can be used as human or veterinary medicine. The compounds of the present invention or pharmaceutical compositions containing them may be administered in unit dosage form by the enteral or parenteral route, such as oral, intramuscular, subcutaneous, nasal, oral, dermal, intraperitoneal or rectal, etc. The route of administration of the compounds of the invention or pharmaceutical compositions containing them may be by injection. The injection includes intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, acupoint injection, etc. The administrati